Key result
Administration of two 5-g doses of idarucizumab combined with hemodialysis successfully reversed dabigatran-induced coagulopathy, maintaining PT and aPTT within appropriate ranges.
Why the study?
Does repeat dosing of idarucizumab with hemodialysis reverse the anticoagulant effects of dabigatran in a patient with acute kidney injury and coagulopathy?
Population
58-year-old obese woman with a history of atrial fibrillation who developed acute kidney injury while taking…
Design
Case_report
Authors
Loading...
May guide reversal of dabigatran coagulopathy with idarucizumab plus hemodialysis; leaves open confirmation in randomized studies.
Case Report (n=1)
Does repeat dosing of idarucizumab with hemodialysis reverse the anticoagulant effects of dabigatran in a patient with acute kidney injury and coagulopathy?
Repeat dosing of idarucizumab combined with hemodialysis successfully reversed dabigatran-induced coagulopathy in a patient with acute kidney injury.
Marino et al. (2016) conducted a case report in Dabigatran-associated coagulopathy (n=1). Idarucizumab plus hemodialysis was evaluated on Reversal of anticoagulant effects (PT and aPTT values). Administration of two 5-g doses of idarucizumab combined with hemodialysis successfully reversed dabigatran-induced coagulopathy, maintaining PT and aPTT within appropriate ranges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: